Brexit would irreparably damage UK pharma industry
A Brexit in the upcoming EU referendum could directly damage the UK pharmaceutical industry, according to NonStop Recruitment.
An analysis by the specialist pharmaceutical and life sciences recruitment consultancy found that the UK leaving the EU would mean the sector would still have to follow regulations to sell in the single market, but that it would have no say over what these regulations were. It would also mean the UK would lose out on the greater patent protection and support for research that it currently gains from being a member state, as well as the expertise of thousands of highly skilled professionals.
Matt Beedle, Team Leader within NonStop Pharma comments: “From our analysis and the many others that have been released it’s clear that the pharmaceutical and life sciences fields would be directly impacted in the case of a Brexit. Yes, the situation isn’t perfect at the moment however, the outlook would still be far worse if we were to vote leave. In this instance there’s a high chance that the EMA (European Medicines Agency) would relocate and therefore many of the pharma companies headquartered in the UK could leave – potentially to Ireland. This is because one of the major reasons many pharma firms have their headquarters in the UK is due to the proximity of the London-based EMA. In addition we’d still need to trade in the single market, however we would no longer have any say in what regulations we would be following, which would obviously damage our competitiveness and would likely weaken our position significantly. The sector would also struggle to keep hold of the thousands of European professionals who currently provide expertise to firms on these shores. We have such a powerful industry here that it seems like a huge error to leave, particularly at a time when our industrial output is growing at its fastest rate for four years, which has been heavily boosted by the pharma sector.”
“For NonStop as a business a leave vote would be particularly unwelcome. We place a big focus on providing the best possible working environment, part of which involves allowing our employees to work in any of our offices across Europe. A Brexit would mean we would face a much larger administrative burden to continue having a diverse workforce, something which we know directly contributes to our success as a business. And it’s not just us that would be affected, the knock on effects would impact all UK businesses that utilise the expertise of European professionals.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance